Aviso Wealth Management Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Aviso Wealth Management lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 113.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,414 shares of the medical research company’s stock after acquiring an additional 1,818 shares during the period. Thermo Fisher Scientific accounts for about 1.1% of Aviso Wealth Management’s investment portfolio, making the stock its 20th largest position. Aviso Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. GLOBALT Investments LLC GA grew its position in Thermo Fisher Scientific by 5.0% in the third quarter. GLOBALT Investments LLC GA now owns 1,102 shares of the medical research company’s stock valued at $682,000 after acquiring an additional 52 shares in the last quarter. Glass Wealth Management Co LLC lifted its stake in Thermo Fisher Scientific by 4.3% in the third quarter. Glass Wealth Management Co LLC now owns 4,562 shares of the medical research company’s stock valued at $2,822,000 after buying an additional 190 shares during the last quarter. Claro Advisors LLC lifted its stake in Thermo Fisher Scientific by 75.3% in the third quarter. Claro Advisors LLC now owns 1,299 shares of the medical research company’s stock valued at $804,000 after buying an additional 558 shares during the last quarter. Peterson Financial Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $27,000. Finally, Tower Bridge Advisors raised its stake in shares of Thermo Fisher Scientific by 0.7% during the third quarter. Tower Bridge Advisors now owns 25,343 shares of the medical research company’s stock valued at $15,677,000 after purchasing an additional 184 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This trade represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock worth $20,651,865 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 3.7 %

NYSE:TMO opened at $513.08 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $464.17 and a 1-year high of $627.88. The business’s 50-day moving average price is $586.43 and its two-hundred day moving average price is $582.39. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $196.25 billion, a price-to-earnings ratio of 32.17, a PEG ratio of 3.39 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the prior year, the company earned $5.69 earnings per share. The company’s revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has approved a share repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.78%.

Analyst Ratings Changes

A number of research firms recently issued reports on TMO. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Sanford C. Bernstein dropped their price target on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, Bernstein Bank lifted their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.